Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis

Veena Mathew,1 Annabel K Wang1,2 1Department of Neurology, UCI ALS and Neuromuscular Center, University of California, Irvine, Orange, CA, USA; 2Neurology Section, Tibor Rubin VA Medical Center, Long Beach, CA, USA Abstract: Hereditary transthyretin amyloidosis is a fatal autosomal dominant disord...

Full description

Bibliographic Details
Main Authors: Mathew V, Wang AK
Format: Article
Language:English
Published: Dove Medical Press 2019-05-01
Series:Drug Design, Development and Therapy
Subjects:
Antisense Oligonucleotide
Familial Amyloid Polyneuropathy
Inotersen
messenger RNA
RNase H
Online Access:https://www.dovepress.com/inotersen-new-promise-for-the-treatment-of-hereditary-transthyretin-am-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/inotersen-new-promise-for-the-treatment-of-hereditary-transthyretin-am-peer-reviewed-article-DDDT

Similar Items